In summary, we have conducted whole-genome and focused sgRNA library CRISPR screens in trastuzumab-resistant HER2-positive breast cancer cell lines to identify genes that promote sensitivity and resistance to T-DM1. This evidence concerns the gene ERBB2 and breast carcinoma.